Abstract 1871P
Background
Evidence suggests that introducing eHealth ecosystems improves the clinical management of chronic pain (CP) in breast cancer patients (BCPs). These tools contribute to overcoming established contextual, social, and individual barriers by monitoring patients' physical health and psychological well-being and early recognizing high-risk patients. Moreover, eHealth ecosystems increase patient participation in treatment decisions through specific decision aids modules, thus enabling shared decisions.
Methods
This pilot study is nested in PainRELife Project (ID:1173269). The primary endpoint was investigating patients' usability experience using an eHealth ecosystem constituted by Nu Platform joined with the PainRELife mobile application. Twenty-five female BCPs (Mage=47, SD=8.41) were enrolled and utilized the mobile application for three months. A set of self-report measures were administered at scheduled time points evaluating the following constructs: physical and mental characteristics; pain experience and intensity; pain self-efficacy; and patients’ preferences for participating in clinical decision-making and shared decision-making. The usability was evaluated by means of the Mobile Application Rating Scale (MARS).
Results
A reduction in pain intensity was observed from baseline (M=5) to 3 months (M=3.72), p<.04. The BCPs reported high values in all subscales of the MARS: engagement (M=3.31); functionality (M=4.14); aesthetics (M= 3.98); quality of the information (M=4.18); subjective quality (M=3.5); influence to change patient behaviors (M=4.05). A positive correlation was found between shared decision-making and engagement (r=.445*), quality of the information (r=.427*), and subjective quality attributed to the mobile application (r=.548**).
Conclusions
The eHealth ecosystems could be valuable aids in supporting clinicians and patients to accomplish the physical, social, and psychological challenges associated with the disease’s trajectory, also improving patients’ participation in treatment decisions allowing the implementation into clinical practice of shared decision-making models.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Applied Research Division for Cognitive and Psychological Science, European Institute of Oncology, IRCCS.
Funding
This work is supported by a grant from Regione Lombardia - “PainRELife, Sustainable and integrat-ed big data ecosystem for continuity of care and decision support for patients with pain" (ID: 1173269). The European Institute of Oncology (Istituto Europeo di Oncologia - IEO, Italy) monitors the scientific, legal, and ethical aspects of the study. Participants are recruited at IEO.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2018P - Novel nomogram based on the expression of DLL3 and PD-L1 for predicting the prognosis of small cell lung cancer patients
Presenter: Jun Zhao
Session: Poster session 05
2019P - Analysis of lung immune prognostic index (LIPI) score in a small cell lung cancer carcinoma (SCLC) cohort, supporting its prognostic use and investigating its predictive potential
Presenter: Mónica Esteban García
Session: Poster session 05
2020P - Circulating micro RNAs (cmiRNAs) as treatment outcome predictors in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab plus carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2021P - Cell-free (cf) DNA as predictive biomarker (B) of treatment outcome in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab, carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2022P - ALBA project: Prognostic impact of laterality in small cell lung cancer
Presenter: Lorenza Landi
Session: Poster session 05
2024P - Supportive measures to control myelosuppression and costs for patients with SCLC with lurbinectedin, CAV or topotecan with or without trilaciclib: A review on the basis of clinical trials
Presenter: Manuel Dómine
Session: Poster session 05
2025P - Stratified control study of neuroendocrine differentiation and potential clinicopathologic markers
Presenter: Li Liu
Session: Poster session 05
2026P - Small cell lung cancer (SCLC) in the KBP-2020-CPHG cohort and comparison with 2000 and 2010
Presenter: Lionel Falchero
Session: Poster session 05
2027P - Immune checkpoint inhibitors in the treatment of small cell lung cancer: A systematic review and meta-analysis
Presenter: Patsy Lee
Session: Poster session 05